Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
A practical review of the neuropathology and neuroimaging of multiple sclerosis.
Ono to enter license agreements with Merck KGaA
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
[Plasmapheresis in central nervous system disorders].
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.

Pages